Compare Vanguard Total International Stock Index Fund ETF (VXUS) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Total International Stock Index Fund ETF vs Zimmer Biomet Holdings Inc — how do they compare? Vanguard Total International Stock Index Fund ETF trades at $84.96 (market cap $665.70B), while Zimmer Biomet Holdings Inc trades at $89.19 (market cap $16.95B). The key difference: Vanguard Total International Stock Index Fund ETF is far larger — about 39.3× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Vanguard Total International Stock Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Total International Stock Index Fund ETF for 55 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| VXUS | ZBH | |
|---|---|---|
Market Cap | $665.70B | $16.95B |
Volume | 4,864,744 | 2,505,240 |
Sector | Sector/Thematic | Health |
52-Week High | $88.41 | $103.98 |
52-Week Low | $72.17 | $79.58 |
Typical Hold Time | 55 Days | 89 Days |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VXUS trades at $84.67, down 0.13% with a bearish technical signal from moving averages and oscillators. The ETF provides diversified international stock exposure excluding U.S. markets, with recent institutional buying interest from firms like QRG Capital and Baird Financial. Support levels cluster around $83-84 while resistance sits at $85.
The outlook remains cautious given technical bearishness, though long-term diversification benefits and institutional accumulation provide support. Key risks include foreign market volatility and currency fluctuations, while the absence of U.S. exposure offers portfolio hedging advantages during domestic downturns.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
